A Business Model for Our Time

Cheryl ProvalPopulation health management (PHM) is a broad term that will generate untold millions in consulting fees in the years to come, but if you add “business model” to the back of the term, we start to get closer to how health care will make the transition from transaction to value. Inevitably, this appears to involve capitation and risk assumption. That's why Health CXO's case study on CareMore's Medicare Advantage plans makes compelling reading. Leveraging community-based clinics, predictive modeling software, and allied health professionals, the plans are targeting the frail elderly with what appear to be excellent results. What exactly is the state of the health of your community? If you are a non-profit hospital or health system, ACA requires your organization to conduct a Community Health Needs Assessment (CHNA) every three years. The temptation is to dismiss the CHNA as yet another burdensome regulatory hoop, but Community Hospital Consulting says the discipline presents an opportunity to refocus mission, something every health care provider should do periodically. Finally, many non-profit hospitals have been engaged in population health management for many years in the form of providing populations without access to federal safety net programs with indigent care. CIO and former HIMSS board chair Charles Christian provides a much-needed common sense approach to the complexities of sharing information across disparate entities as we move into the era of population health management. Risk assumption is risky business. Let me know how your organization is approaching the challenge and what you need from other stakeholders to succeed. I promise to share your thoughts in the next issue of Health CXO. Cheryl Proval cproval@healthcxo.com
Cheryl Proval,

Vice President, Executive Editor, Radiology Business

Cheryl began her career in journalism when Wite-Out was a relatively new technology. During the past 16 years, she has covered radiology and followed developments in healthcare policy. She holds a BA in History from the University of Delaware and likes nothing better than a good story, well told.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.